2026-10-14T03:25:44Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34012413 2026-09-28T08:32:05Z category_19 portal_316 item_type_3 month_year_09_2026

Supplementary file 1_Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials.docx Fen Liu (317808) Yong Pan (24522) Jinlan Li (7510904) Xiaojie Hu (1541101) Guisen Yin (25121193) Pharmacology antibody-drug conjugates effectiveness HER2 positive breast cancer network meta-analysis safety Background<p>Antibody-drug conjugates (ADCs) have become the standard treatment for HER2-positive(HER2+)advanced breast cancer following the failure of trastuzumab or taxane. Nevertheless, there are no direct head-to-head trials comparing different ADCs.</p>Methods<p>We searched PubMed, Embase, the Cochrane Library and abstracts from major oncology conferences, and included phase III randomized controlled trials (RCTs) investigating HER2-targeting ADCs. We conducted a frequentist random-effects NMA, and utilized the P-score to rank the efficacy of included treatments. The outcome indicators include progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs).</p>Results<p>Seven RCTs involving 3,160 patients and seven ADCs (T-DM1, ARX788, A166, SHR-A1811, RC48, DP303c and T-DXd) were included in our research. All ADCs showed a significant PFS benefit versus chemotherapy plus tyrosine kinase inhibitor (Chem + TKI). T-DXd showed the most favorable PFS (HR = 0.18, 95%CI: 0.13–0.25), followed by SHR-A1811 (HR = 0.22, 95%CI: 0.15–0.33) compared with Chem + TKI. SHR-A1811 showed a promising OS signal(HR = 0.31, 95% CI: 0.14–0.69), followed by T-DXd (HR = 0.41, 95% CI: 0.26–0.66) compared with Chem + TKI. For safety, T-DXd exhibited the highest odds for all-grade TRAEs relative to all included control treatments, with statistically significant differences identified when compared with T-DM1 and Chem + TKI., T-DM1 demonstrated better safety characteristics for grade ≥3 TRAEs, with a significantly lower odds of occurrence than SHR-A1811, ARX788, DP303c, and Chem + TKI.</p>Conclusion<p>Included anti-HER2 ADCs significantly improve PFS over Chem + TKI, among which T-DXd and SHR-A1811 deliver notable survival benefits. Although T-DXd is associated with a higher odd of all-grade TRAEs and T-DM1 exhibits favourable grade ≥3 safety.</p>Systematic Review Registration<p>https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420251234345, identifier CRD420251234345.</p> 2026-09-28T08:32:05Z Dataset Dataset 10.3389/fphar.2026.1921830.s001 https://figshare.com/articles/dataset/Supplementary_file_1_Efficacy_and_safety_of_antibody-drug_conjugates_in_pretreated_HER2-positive_advanced_breast_cancer_a_network_meta-analysis_of_randomized_controlled_trials_docx/34012413 CC BY 4.0